B.S. – Kean University, NJ, USA

Mary Hanneman serves as the Chief Executive Officer of ProAllostera Pharmaceuticals Inc., bringing over 25 years of extensive experience in corporate leadership and consumer-focused research to the team. Mary holds a Bachelor of Science in Management Science from Kean University, where she graduated magna cum laude. She leverages her deep expertise in organizational management and strategic business operations to guide the company’s vision and drive growth.

M.Sc – University of Lodz, Poland

Ph.D. – University of Lodz, Poland

Postdoc – University of Illinois

Postdoc – Harvard University

Postdoc – Univ. of Texas Health Sci. Ctr. at San Antonio

Pawel Osmulski serves as President and Co-Founder of ProAllostera Pharmaceuticals Inc. Separately from this role, Dr. Osmulski is an Associate Professor whose academic research focuses on proteasome biophysics, protein–ligand interactions, and single-molecule analysis of proteasome structure and dynamics. His laboratory uses atomic force microscopy and biochemical approaches to study proteasome gate regulation, aging-related proteasome remodeling, and the effects of proteasome-targeting compounds. His work has contributed to the development and characterization of peptide-based proteasome activators for neurodegenerative disease.

M.Sc – University of Lodz, Poland

Ph.D. – University of Lodz, Poland

Postdoc – Univ. of Arizona

Postdoc – Harvard University

Postdoc – Massachusetts Institute of Technology

Maria Gaczynska serves as Treasurer and Co-Founder of ProAllostera Pharmaceuticals Inc. Separately from this role, Dr. Gaczynska is an Associate Professor whose academic laboratory investigates the biochemistry, biophysics, and structural dynamics of the proteasome. Her research focuses on proteasome allosteric regulation, proteasome gate dynamics, atomic force microscopy, and the development of proteasome-modulating compounds. Her laboratory has helped define how proteasome structure and activity are altered in aging and neurodegenerative disease, supporting proteasome activation as a therapeutic strategy

B.A. / M.A Oxford University, UK

Ph.D. – Univ. Southern California

Postdoc – UCLA

Postdoc – Univ. of Michigan

Andrew Pickering serves as Secretary and Co-Founder of ProAllostera Pharmaceuticals Inc. Separately from this role, Dr. Pickering is an Associate Professor whose academic laboratory investigates the mechanisms by which aging impairs protein homeostasis and increases vulnerability to neurodegenerative disease. His research focuses on proteasome dysfunction, protein translation, brain aging, and Alzheimer’s disease, and has shown that restoring proteasome activity can improve pathological and cognitive outcomes in aging and disease models.